Mahoney Stephen F. 4

4 · Viridian Therapeutics, Inc.\DE · Filed Mar 4, 2026

Form 4

Period: 2026-03-02

DirectorPresident and CEO

Transactions

Exercise/Conversion
Common Stock
[F2][F5]
2026-03-03+18,357→ 40,757 total
Tax Payment
Common Stock
[F5]
2026-03-03$29.32/sh−7,627$223,624→ 33,130 total
Award
Stock Option (Right to Buy)
[F1]
2026-03-02+559,600→ 559,600 total
Exercise: $30.25Exp: 2036-03-02→ Common Stock (559,600 underlying)
Award
Restricted Stock Units
[F2][F3]
2026-03-02+111,900→ 111,900 total
→ Common Stock (111,900 underlying)
Exercise/Conversion
Restricted Stock Units
[F2][F4]
2026-03-03−18,357→ 55,071 total
→ Common Stock (18,357 underlying)

Footnotes (5)

[F1]The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026.
[F2]Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.
[F3]The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.
[F4]The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date.
[F5]Includes 1,000 shares acquired under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan (the "ESPP") on March 17, 2025 in transactions that were exempt under Rule 16b-3(c).

Signature

Jennifer Tousignant, Attorney-in-fact|2026-03-04

Documents

1 file